Eteplirsen delays cardiac decline in DMD clinical trials
A recent study found that individuals with DMD who receive eteplirsen have slower declines in cardiac function than those who do not.
News
-
-
World Duchenne Awareness Day 2025: How to get involved
World Duchenne Awareness Day takes place on September 7 each year to raise awareness of DMD and advocate for improved research and education.
-
Claims study finds costs rapidly increase as DMD progresses
A German health care claims analysis finds that direct and indirect costs for DMD soar as patients progress through the disease stages.
-
Study shows givinostat is effective in patients with DMD long-term
An open-label extension of the EPIDYS clinical trial found that givinostat is safe and delays disease progression in patients with DMD.
-
KER-065 granted FDA Orphan Drug designation for DMD
KER-065, an experimental Duchenne muscular dystrophy (DMD) drug, has been granted Orphan Drug designation by the FDA.
-
Case report: Patient with DMD receives successful heart transplant
A young man with DMD received a heart transplant at 18 years old and reports positive outcomes after 3.5 years.
-
Patients face new challenges as Duchenne gene therapies advance
Recent gene therapies for Duchenne muscular dystrophy offer hope but also bring risks, including patient deaths.
-
Newborn screening for Duchenne muscular dystrophy offers earlier answers
Earlier detection of DMD through newborn screening could give families more time to access treatment and plan care.
-
New review highlights the complexity of treating cognitive aspects of DMD
One-third of individuals with DMD experience cognitive or behavioral differences, but treating DMD’s impact on the brain poses challenges.
-
Study finds postural control clearly declines in patients with DMD over a one-year period
Patients with DMD significantly lose postural control over a relatively short span of time.
